Abbvie Inc ABBV

$283.12 -5.96 (-2.06%)

Valuation

Market cap
499,437,056,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
26.26
Forward PE
20.48
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
1,734,022
Avg volume
4,608,324
Day's range
$282.15 – $289.00
Shares out
1,766,793,000
Stochastic %K
91%
Beta
0.24
Analysts
Strong Sell
Price target
$282.37

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

55X_ROI_Q1_2026 Oct 21, 4:24 PM
$SLS we are Now + 10 Months Later than ANTICIPATED “ should that even occur later than anticipated, from a mathematical standpoint, and the fact we administer GPs even three years out, every passing month may increase the probability of a successful study due to a Potential Gps Effect as we have seen in our previous CR1 and CR2 Studies far surpassing median overall survival vs standard of care - when the 80th event arises, we will inform the public…” “ We expect 80th event by year end, but its an event driven study, blinded to outcomes survival times appear unexpectedly long, due to significantly longer than expected survival, the timing of final analysis difficult to predict w any certainty and the 80th event may occur at a different time than currently expected.” $MRNA $ABBV
0 replies
55X_ROI_Q1_2026 Oct 21, 4:10 PM
$SLS $ABBV $RHHBY $BMY https://www.youtube.com/watch?t=779&v=nCtrZavKCuM Direct Link to Minute Mark 12:47 - where Angelos Discusses expected Timeline to see the 80th Event - End of 2025, - and what it Means if it Occurs Later. Now we Know its Been + 10 Months Past the Expected Timeline +10 Months of Additional OVERALL SURVIVAL Beyond What Dr. Kantarjian the Chair of MD Anderson's Leukemia Dept., - would expect, based on his Direct Knowledge of BAT. Dr. Kantarjian is running the Global SLS Phase 3 and Chairs the REGAL P3 Steering Committee.
0 replies
Oldpuck Oct 21, 3:51 PM
$ABBV Did ABBV miss earnings today too like ABT
0 replies
55X_ROI_Q1_2026 Oct 21, 3:14 PM
$SLS $ABBV $BMY This $2.3B Manipulated Equity is worth Close to $50B the Instant the IMMINENTLY DUE GPs P3 Results are Announced. $MRNA
0 replies
jbess22 Oct 21, 12:04 PM 0 replies
Techdamentals Oct 21, 3:41 AM
$ABBV rose 2.1% to $288.66 on Tuesday Oct 20, near its 52-week high, as drug stocks led a rally that put health care at an all-time high. I found no company-specific news. I checked it against the Techdamentals IV Calculator. What is it worth? 👇 https://techdamentals.com/v/ABBV?ref=st Educational, not advice.
0 replies
55X_ROI_Q1_2026 Oct 21, 2:54 AM
$SLS $ABBV $RHHBY $BMY SLS Ceo Discusses CR1 SOC vs GPS Phase 2 in the Same CR1 Setting
0 replies
55X_ROI_Q1_2026 Oct 21, 1:12 AM
$SLS $2.3B $ABBV 202M SLS Shares Outstanding 202M / $50B Mcap $247 Per SLS Share Gps has a $28B Total Addressable Market - Just for AML Remission Will set Records for Patient Uptake rates w 2X 4X OS benefits, pristine safety profile, ease of manufacture, storage and Administration. Ip rights into 2037, FDA / EU Orphan and Fast Track Designations. Phase 3 Registrational Results w Miraculous Survival Data will be Announced Any Day Now. $MRNA and MRK added $80B in Market Value in the Days after thier Cancer Vaccine results were announced. Something Very Similar is about to Happen Here. //
0 replies